Cognition Therapeutics Inc $CGTX

What the company doesAI summary of filing

Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. The company's lead product candidate, zervimesine (CT1812), is an orally delivered compound designed to protect neuronal synapses by preventing the binding of pathogenic protein oligomers including beta-amyloid and alpha-synuclein, which are linked to Alzheimer's disease and dementia with Lewy bodies. Zervimesine has completed Phase 2 clinical trials in mild-to-moderate Alzheimer's disease and dementia with Lewy bodies, with an ongoing Phase 2 trial in mild cognitive impairment and early-stage Alzheimer's disease; the company has received approximately $171 million in cumulative non-dilutive grants primarily from the National Institute of Aging to fund its clinical development. Cognition is pre-revenue and currently focused on advancing zervimesine through additional clinical trials to support regulatory approval. [10-K 2026-03-26]

Segments: Zervimesine (CT1812) for Alzheimer's disease, Zervimesine (CT1812) for dementia with Lewy bodies, Zervimesine (CT1812) for geographic atrophy secondary to dry age-related macular degeneration